Why Akebia Therapeutics Stock Is Skyrocketing Today

What happened

Shares ofAkebia Therapeutics (NASDAQ: AKBA)have jumped today, rising 17.8% as of 11:49 a.m. EDT, following the announcement that Akebia andVifor Pharma Group have agreed to an exclusive license agreement withFresenius Medical Care(NYSE: FMS) for theexperimental anemia drugvadadustat. Vadadustat is presently in late-stage development as a treatment foranemia associated with chronic kidney disease (CKD).

Image source: Getty Images.

So what

The big-ticket item forAkebia is thatVifor Pharma agreed to make a $50 million equity investment in Akebia at $14 per share as part of this deal. In other words, Vifor just became one ofAkebia's largest stakeholders, which should be a stabilizing influence on this small-cap drugmaker's share price moving forward.

Now what

According to the press release,Akebia stands to make an additional $20 million uponvadadustat's approval in the United States and inclusion in a bundled reimbursement model. More importantly, though, this licensing agreement largely assures thatvadadustat will get off to a hot start once it enters the market.Fresenius, after all, is the largestkidney dialysis provider in theU.S., with a 40% market share -- implying that the deck will be stacked in the drug's favor right out of the gate.

Akebia appears to be building a solid foundation for growth through vadadustat's robust late-stage development program. So, even though it does have to share a portion of the drug's profits and milestone payments with its U.S. collaboratorOtsuka Pharmaceutical Co. Ltd, this up-and-coming drugmaker may be worth checking out.

10 stocks we like better than Akebia TherapeuticsWhen investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Akebia Therapeutics wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of May 1, 2017

George Budwell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.